...new evidence and price,” said ICER CMO David Rind. Going long What set Revlimid and Genvoya...
...apart was new evidence of added benefit over existing treatments based on long-term data. For Genvoya...
...Sciences Inc. (NASDAQ:GILD) submitted long-term data from randomized controlled trials to ICER that showed that Genvoya...

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) Enbrel etanercept $5,782.8 $3,925.2 $5,233.6 -9% Gilead Sciences Inc. (NASDAQ:GILD) Genvoya...

...its 4Q16 sales figures of $3.2 billion (see BioCentury Extra, Feb. 6) . HIV drugs Genvoya...

...5% Gilead Sciences Inc. (NASDAQ:GILD) Epclusa sofosbuvir/velpatasvir $1,752.0 $2,945.0 $3,926.7 124% Gilead Sciences Inc. (NASDAQ:GILD) Genvoya...

...partially offset by growth in HIV. The company reported $769 million in 1Q17 sales of Genvoya...
...TAF), up from $158 million in 1Q16 and beating the $647.9 million consensus. FDA approved Genvoya...
...consensus. The company gained $0.48 to $68.59 on Tuesday, and reported earnings after market close. Becky Simon Genvoya Harvoni Sovaldi Gilead...

...category rose to $3.4 billion in 4Q16, up from $3 billion in 4Q15. Sales of Genvoya...

...3Q15. The company attributed the increase largely to uptake of tenofovir alafenamide-based treatments such as Genvoya...

...of HIV treatment Genvoya were $302 million in 2Q16, beating the consensus estimate. FDA approved Genvoya...

...and Efficiency in Health Care (IQWiG) issued a dossier of early benefit assessment for Genvoya tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine...

...of Gilead’s patents covering TAF.” The non-profit said Gilead’s November 2015 launch of HIV drug Genvoya...
...argued Gilead “knowingly, willfully, and wrongfully maintained its monopoly power by improperly bundling” TAF into Genvoya...
...wishing to enter the market would have to invalidate all 12 Orange Book patents covering Genvoya...